Company / PP&E (Net)
Abbott Laboratories PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$11.8B
FY2025
5-year range
$9.0B / $11.8B
FY2021-FY2025
Trend
+10.9%
vs FY2024
Sector context
#2 of 130
Health Care
What the data says
Among 130 Health Care companies, Abbott Laboratories is in the top 2% for pp&e (net). PP&E (Net) has increased for 4 consecutive years, from $9.0B in FY2021 to $11.8B in FY2025.
Based on SEC 10-K filings.
$11.8B in FY2025 with a 5-year CAGR of +5.5%. Ranks 2nd among 130 companies in Health Care.
Improved from $10.2B to $11.8B over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +8.8%
- 5-Year CAGR
- +5.5%
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 130This company $11.8B Sector average $1.3B
▼
+779.0% above sector average
Key checks
Key Insights
- Abbott Laboratories's pp&e (net) has grown for 4 consecutive years.
- 5-year CAGR of +5.5%, indicating consistent growth.
- In FY2025, pp&e (net) increased 10.9% year-over-year.
- Ranks #2 out of 130 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 31.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 27.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.8B | +10.9% |
| FY2024 | $10.7B | +5.0% |
| FY2023 | $10.2B | +10.8% |
| FY2022 | $9.2B | +2.3% |
| FY2021 | $9.0B | -0.8% |
| FY2020 | $9.0B | +12.3% |
| FY2019 | $8.0B | +6.3% |
| FY2018 | $7.6B | -0.6% |
| FY2017 | $7.6B | +33.3% |
| FY2016 | $5.7B | -0.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026